Literature DB >> 23688214

Cognitive consequences of high Aβ amyloid in mild cognitive impairment and healthy older adults: implications for early detection of Alzheimer's disease.

Yen Ying Lim1, Kathryn A Ellis1, Karra Harrington1, Adrian Kamer1, Robert H Pietrzak2, Ashley I Bush1, David Darby1, Ralph N Martins3, Colin L Masters1, Christopher C Rowe4, Greg Savage5, Cassandra Szoeke1, Victor L Villemagne1, David Ames6, Paul Maruff1.   

Abstract

BACKGROUND: It has been proposed that only mild cognitive impairment (MCI) with high Aβ amyloid is indicative of incipient Alzheimer's disease (AD), yet MCI with low Aβ amyloid may reflect other neurodegenerative processes. We aimed to determine the extent to which high Aβ amyloid influenced cognitive function in healthy older adults and adults with MCI.
METHOD: Healthy controls (HC; n = 178) and adults with MCI (n = 56) enrolled in the Australian Imaging, Biomarkers, and Lifestyle study, underwent positron emission tomography neuroimaging for Aβ amyloid and completed an extensive neuropsychological battery, assessing the cognitive domains of verbal and visual episodic memory, executive function, visuoconstruction, attention and processing speed, and language at baseline.
RESULTS: MCI with low Aβ performed worse than MCI with high Aβ on measures of executive function, attention, visuoconstruction and language. No differences were observed between HC high and low Aβ groups. When compared with HC with low Aβ, both MCI high and low Aβ groups performed worse on measures of episodic memory. However, only the MCI low Aβ group performed worse than HC low Aβ on measures of executive function, attention, visuoconstruction, and language.
CONCLUSIONS: When compared with HC with low Aβ amyloid, MCI with high Aβ amyloid present with impairments restricted to episodic memory, and the episodic memory impairments in MCI with low Aβ amyloid were accompanied by impairments in executive function, attention, visuoconstruction, and language, suggesting that MCI with high Aβ amyloid reflects prodromal AD, although further longitudinal data is required to confirm this.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23688214     DOI: 10.1037/a0032321

Source DB:  PubMed          Journal:  Neuropsychology        ISSN: 0894-4105            Impact factor:   3.295


  13 in total

1.  Tau and Amyloid-β Cerebrospinal Fluid Biomarkers have Differential Relationships with Cognition in Mild Cognitive Impairment.

Authors:  Charles B Malpas; Michael M Saling; Dennis Velakoulis; Patricia Desmond; Terence J O'Brien
Journal:  J Alzheimers Dis       Date:  2015       Impact factor: 4.472

2.  Validation of the Spanish Version of the LASSI-L for Diagnosing Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Jordi A Matías-Guiu; Rosie E Curiel; Teresa Rognoni; María Valles-Salgado; Marta Fernández-Matarrubia; Roshan Hariramani; Alejandro Fernández-Castro; Teresa Moreno-Ramos; David A Loewenstein; Jorge Matías-Guiu
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

3.  Identification of Successful Cognitive Aging in the Alzheimer's Disease Neuroimaging Initiative Study.

Authors:  Feng V Lin; Xixi Wang; Rachel Wu; George W Rebok; Benjamin P Chapman
Journal:  J Alzheimers Dis       Date:  2017       Impact factor: 4.472

4.  Diagnostic and Prognostic Accuracy of the Cogstate Brief Battery and Auditory Verbal Learning Test in Preclinical Alzheimer's Disease and Incident Mild Cognitive Impairment: Implications for Defining Subtle Objective Cognitive Impairment.

Authors:  Nikki H Stricker; Emily S Lundt; Sabrina M Albertson; Mary M Machulda; Shehroo B Pudumjee; Walter K Kremers; Clifford R Jack; David S Knopman; Ronald C Petersen; Michelle M Mielke
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

5.  Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease.

Authors:  Piers Johnson; Luke Vandewater; William Wilson; Paul Maruff; Greg Savage; Petra Graham; Lance S Macaulay; Kathryn A Ellis; Cassandra Szoeke; Ralph N Martins; Christopher C Rowe; Colin L Masters; David Ames; Ping Zhang
Journal:  BMC Bioinformatics       Date:  2014-12-08       Impact factor: 3.169

Review 6.  Cognitive impairment and decline in cognitively normal older adults with high amyloid-β: A meta-analysis.

Authors:  Jenalle E Baker; Yen Ying Lim; Robert H Pietrzak; Jason Hassenstab; Peter J Snyder; Colin L Masters; Paul Maruff
Journal:  Alzheimers Dement (Amst)       Date:  2016-10-18

7.  Neuropsychology and neuroimaging profiles of amyloid-positive versus amyloid-negative amnestic mild cognitive impairment patients.

Authors:  Clémence Tomadesso; Vincent de La Sayette; Robin de Flores; Pierrick Bourgeat; Victor L Villemagne; Stéphanie Egret; Francis Eustache; Gaël Chételat
Journal:  Alzheimers Dement (Amst)       Date:  2018-03-17

8.  Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis.

Authors:  Sarah J A Carr; Judith Jaeger; Shijia Bian; Ping He; Nancy Maserejian; Wenting Wang; Paul Maruff; Ahmed Enayetallah; Yanming Wang; Zhengyi Chen; Alan Lerner; Curtis Tatsuoka
Journal:  Front Neurol       Date:  2019-09-13       Impact factor: 4.003

Review 9.  Current advances in digital cognitive assessment for preclinical Alzheimer's disease.

Authors:  Fredrik Öhman; Jason Hassenstab; David Berron; Michael Schöll; Kathryn V Papp
Journal:  Alzheimers Dement (Amst)       Date:  2021-07-20

10.  Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness.

Authors:  Karra D Harrington; Yen Ying Lim; David Ames; Jason Hassenstab; Simon M Laws; Ralph N Martins; Stephanie Rainey-Smith; Joanne Robertson; Christopher C Rowe; Olivier Salvado; Vincent Doré; Victor L Villemagne; Peter J Snyder; Colin L Masters; Paul Maruff
Journal:  Alzheimers Dement (Amst)       Date:  2017-06-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.